Literature DB >> 29273393

Macrophages: Key orchestrators of a tumor microenvironment defined by therapeutic resistance.

Kristen B Long1, Arthur I Collier1, Gregory L Beatty2.   

Abstract

Macrophages have emerged as promising therapeutic targets in cancer. Within tumor tissue, macrophages foster tumor development, invasion, and metastasis. As the phenotype of macrophages is inherently pliable and dependent on cues received from the surrounding microenvironment, macrophages co-evolve with malignant and other non-malignant cells during cancer progression. In doing so, they establish a microenvironment that is therapeutically resistant and thwarts the productivity of T cell immunosuveillance. Strategies designed to deplete, inhibit, or redirect macrophages with anti-tumor activity are being explored to reverse the pro-tumor properties of macrophages that are commonly observed in cancer. In this review, we discuss our current understanding of the mechanisms that regulate macrophage recruitment to tumors, their impact on the tumor microenvironment, and their promise as therapeutic targets for improving the efficacy of cytotoxic- and immune-based therapies.
Copyright © 2017 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Cancer; Chemotherapy; Immunotherapy; Macrophages; Resistance; Tumor

Mesh:

Year:  2017        PMID: 29273393      PMCID: PMC6008174          DOI: 10.1016/j.molimm.2017.12.003

Source DB:  PubMed          Journal:  Mol Immunol        ISSN: 0161-5890            Impact factor:   4.407


  127 in total

Review 1.  Cancer immunotherapy: activating innate and adaptive immunity through CD40 agonists.

Authors:  Gregory L Beatty; Yan Li; Kristen B Long
Journal:  Expert Rev Anticancer Ther       Date:  2016-12-14       Impact factor: 4.512

Review 2.  Functio Laesa: Cancer Inflammation and Therapeutic Resistance.

Authors:  Mingen Liu; Anusha Kalbasi; Gregory L Beatty
Journal:  J Oncol Pract       Date:  2017-03       Impact factor: 3.840

Review 3.  Programmed cell removal: a new obstacle in the road to developing cancer.

Authors:  Mark P Chao; Ravindra Majeti; Irving L Weissman
Journal:  Nat Rev Cancer       Date:  2011-12-08       Impact factor: 60.716

4.  CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans.

Authors:  Gregory L Beatty; Elena G Chiorean; Matthew P Fishman; Babak Saboury; Ursina R Teitelbaum; Weijing Sun; Richard D Huhn; Wenru Song; Dongguang Li; Leslie L Sharp; Drew A Torigian; Peter J O'Dwyer; Robert H Vonderheide
Journal:  Science       Date:  2011-03-25       Impact factor: 47.728

Review 5.  Protective and pathogenic functions of macrophage subsets.

Authors:  Peter J Murray; Thomas A Wynn
Journal:  Nat Rev Immunol       Date:  2011-10-14       Impact factor: 53.106

6.  Targeting Suppressive Myeloid Cells Potentiates Checkpoint Inhibitors to Control Spontaneous Neuroblastoma.

Authors:  Yumeng Mao; Nina Eissler; Katarina Le Blanc; John Inge Johnsen; Per Kogner; Rolf Kiessling
Journal:  Clin Cancer Res       Date:  2016-03-08       Impact factor: 12.531

7.  The cellular and molecular origin of tumor-associated macrophages.

Authors:  Ruth A Franklin; Will Liao; Abira Sarkar; Myoungjoo V Kim; Michael R Bivona; Kang Liu; Eric G Pamer; Ming O Li
Journal:  Science       Date:  2014-05-08       Impact factor: 47.728

8.  Macrophages eat cancer cells using their own calreticulin as a guide: roles of TLR and Btk.

Authors:  Mingye Feng; James Y Chen; Rachel Weissman-Tsukamoto; Jens-Peter Volkmer; Po Yi Ho; Kelly M McKenna; Samuel Cheshier; Michael Zhang; Nan Guo; Phung Gip; Siddhartha S Mitra; Irving L Weissman
Journal:  Proc Natl Acad Sci U S A       Date:  2015-02-02       Impact factor: 11.205

9.  Engineered SIRPα variants as immunotherapeutic adjuvants to anticancer antibodies.

Authors:  Kipp Weiskopf; Aaron M Ring; Chia Chi M Ho; Jens-Peter Volkmer; Aron M Levin; Anne Kathrin Volkmer; Engin Ozkan; Nathaniel B Fernhoff; Matt van de Rijn; Irving L Weissman; K Christopher Garcia
Journal:  Science       Date:  2013-05-30       Impact factor: 47.728

Review 10.  Metabolic reprograming in macrophage polarization.

Authors:  Silvia Galván-Peña; Luke A J O'Neill
Journal:  Front Immunol       Date:  2014-09-02       Impact factor: 7.561

View more
  17 in total

Review 1.  Cellular determinants and therapeutic implications of inflammation in pancreatic cancer.

Authors:  Meredith L Stone; Gregory L Beatty
Journal:  Pharmacol Ther       Date:  2019-05-31       Impact factor: 12.310

2.  Pomalidomide Alters Pancreatic Macrophage Populations to Generate an Immune-Responsive Environment at Precancerous and Cancerous Lesions.

Authors:  Ligia I Bastea; Geou-Yarh Liou; Veethika Pandey; Alicia K Fleming; Christina A von Roemeling; Heike Doeppler; Zhimin Li; Yushi Qiu; Brandy Edenfield; John A Copland; Han W Tun; Peter Storz
Journal:  Cancer Res       Date:  2019-01-29       Impact factor: 12.701

3.  Macrophages potentiate STAT3 signaling in skeletal muscles and regulate pancreatic cancer cachexia.

Authors:  Surendra K Shukla; Spas D Markov; Kuldeep S Attri; Enza Vernucci; Ryan J King; Aneesha Dasgupta; Paul M Grandgenett; Michael A Hollingsworth; Pankaj K Singh; Fang Yu; Kamiya Mehla
Journal:  Cancer Lett       Date:  2020-04-25       Impact factor: 8.679

Review 4.  Payload Delivery: Engineering Immune Cells to Disrupt the Tumour Microenvironment.

Authors:  Daniel Fowler; Callum Nattress; Alba Southern Navarrete; Marta Barisa; Jonathan Fisher
Journal:  Cancers (Basel)       Date:  2021-11-29       Impact factor: 6.639

Review 5.  CAR T Cell Therapy of Non-hematopoietic Malignancies: Detours on the Road to Clinical Success.

Authors:  Kristen B Long; Regina M Young; Alina C Boesteanu; Megan M Davis; J Joseph Melenhorst; Simon F Lacey; David A DeGaramo; Bruce L Levine; Joseph A Fraietta
Journal:  Front Immunol       Date:  2018-12-03       Impact factor: 7.561

Review 6.  Ontogeny of Tumor-Associated Macrophages.

Authors:  Marie Laviron; Alexandre Boissonnas
Journal:  Front Immunol       Date:  2019-07-31       Impact factor: 7.561

7.  CAF secreted miR-522 suppresses ferroptosis and promotes acquired chemo-resistance in gastric cancer.

Authors:  Haiyang Zhang; Ting Deng; Rui Liu; Tao Ning; Haiou Yang; Dongying Liu; Qiumo Zhang; Dan Lin; Shaohua Ge; Ming Bai; Xinyi Wang; Le Zhang; Hongli Li; Yuchong Yang; Zhi Ji; Hailong Wang; Guoguang Ying; Yi Ba
Journal:  Mol Cancer       Date:  2020-02-27       Impact factor: 27.401

Review 8.  Diverse Functions of Macrophages in Different Tumor Microenvironments.

Authors:  Ming Yang; Daniel McKay; Jeffrey W Pollard; Claire E Lewis
Journal:  Cancer Res       Date:  2018-09-11       Impact factor: 12.701

9.  Transcriptional and Microenvironmental Landscape of Macrophage Transition in Cancer: A Boolean Analysis.

Authors:  Ugo Avila-Ponce de León; Aarón Vázquez-Jiménez; Meztli Matadamas-Guzman; Rosana Pelayo; Osbaldo Resendis-Antonio
Journal:  Front Immunol       Date:  2021-06-10       Impact factor: 7.561

10.  IL-20 antagonist suppresses PD-L1 expression and prolongs survival in pancreatic cancer models.

Authors:  Shao-Wei Lu; Hong-Chin Pan; Yu-Hsiang Hsu; Kung-Chao Chang; Li-Wha Wu; Wei-Yu Chen; Ming-Shi Chang
Journal:  Nat Commun       Date:  2020-09-14       Impact factor: 14.919

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.